Prasad Manchem
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2022First federal award
$2.3MFederal grants as PI3 awards
3Patents grantedLatest Sep 29, 2026
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
3 awards · $2.3M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| May 5, 2026 | NIH | SBIR Phase II An innovative, non-thiazolidinedione pan-PPAR agonist therapeutic for alcoholic hepatitis: IND-enabling safety and toxicological evaluation | $1.0M | PLEIOGENIX INC. |
| May 14, 2025 | NIH | SBIR Phase II An innovative, non-thiazolidinedione pan-PPAR agonist therapeutic for alcoholic hepatitis: IND-enabling safety and toxicological evaluation | $1.0M | PLEIOGENIX INC. |
| May 12, 2022 | NIH | SBIR Phase I An innovative non-thiazolidinedione pan-PPAR agonist therapeutic for Alcoholic Hepatitis | $296K | PLEIOGENIX INC. |
4 patents as inventor
- US 12257234PLEIOGENIX INC.Mar 25, 2025
- US 12485106PLEIOGENIX INC.Dec 2, 2025
- US 12746225PLEIOGENIX INC.Sep 29, 2026
- US PLEIOGENIX INC.—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#837
Awards as PI#822
Patents#63
Companies
- PLEIOGENIX INC.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.